Vrije Universiteit Brussel

Vib Vzw

Jens De Vos

Nick Devoogdt

Tony Lahoutte

Matthias D'Huyvetter

Patrick De Baetselier

Geert Raes

Steve Schoonooghe

Sophie Hernot

Gezim Bala

Simon Tierens

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a γ-emitter and β-emitter.

Radiolabelled antibody fragments for use in treating cancer

Provided herein are methods, kits, and compositions for stratifying and treating subjects, e.g., subjects having cancer. In some examples, the methods involve use of a radiolabelled heavy chain variable domain derived from a heavy chain antibody (V), or a functional fragment thereof, as both a screening agent and a treatment agent. In some examples, the V, or a functional fragment thereof, that is radiolabelled with a radioisotope that is both a &#x3b3;-emitter and &#x3b2;-emitter.

The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (V) or functional fragments thereof, wherein said Vor functional fragment thereof specifically binds to a target protein that is present on and/or specific for a solid tumor or cancer cell, e.g., HER2. The application further provides nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions, and in particular to pharmaceutical compositions that comprise such polypeptides, nucleic acids and/or host cells. The application further provides such polypeptides, nucleic acids, host cells and/or compositions, for use in methods for the prevention and/or treatment of cancer.

Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer

The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Growing community of inventors

Strombeek-Bever, Belgium

Jens De Vos